NUVB
HEALTHCARENuvation Bio Inc
AI Insight
What's Moving NUVB Today?
No stock-specific AI insight has been generated for NUVB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.81$9.75
$6.51
Fundamentals
Market Cap$2.0B
P/E Ratio—
EPS$-0.43
Dividend Yield—
Dividend / Share—
ROE-39.5%
Profit Margin-102.1%
Debt / Equity—
Trading
Volume6.2M
Avg Volume (10D)—
Shares Outstanding347.2M
NUVB News
21 articles- Veteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains MomentumMotley Fool·Jun 17, 2026
- Here’s What the Acquisition of Nuvalent Means for Nuvation Bio (NUVB)Yahoo Finance·Jun 16, 2026
- Spotlight On Promising Penny Stocks For June 2026Yahoo Finance·Jun 10, 2026
- Nuvation Bio to Present at the Jefferies Global Healthcare ConferenceYahoo Finance·May 27, 2026
- Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual MeetingYahoo Finance·May 27, 2026
- Nuvation Bio Sharpens IBTROZI Focus With Thermo Fisher And FDA StepsYahoo Finance·May 18, 2026
- Thermo Fisher Deepens Oncology Role With Ibtrozi Manufacturing MilestoneYahoo Finance·May 18, 2026
- Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio BetMotley Fool·May 15, 2026
- Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting BackMotley Fool·May 15, 2026
- Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 SharesMotley Fool·May 15, 2026
- Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying.Yahoo Finance·May 15, 2026
- Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung CancerYahoo Finance·May 13, 2026
- Is Nuvation Bio (NUVB) the Best Penny Stock to Buy Before It Explodes?Yahoo Finance·May 13, 2026
- Nuvation Bio Inc. Beat Analyst Profit Forecasts, And Analysts Have New EstimatesYahoo Finance·May 8, 2026
- Undervalued Penny Stocks To Watch In May 2026Yahoo Finance·May 6, 2026
- Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung CancerYahoo Finance·May 6, 2026
- Nuvation Bio to Participate in Upcoming Investor ConferencesYahoo Finance·May 5, 2026
- Nuvation Bio Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- Nuvation Bio Inc. Q1 2026 Earnings Call SummaryMoby·May 5, 2026
- Nuvation Bio (NUVB) Q1 2026 Earnings TranscriptMotley Fool·May 4, 2026
- Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB)The Motley Fool·Apr 13, 2026
All 21 articles loaded
Price Data
Open$6.08
Previous Close$6.04
Day High$6.60
Day Low$6.08
52 Week High$9.75
52 Week Low$1.81
52-Week Range
$1.81$9.75
$6.51
Fundamentals
Market Cap$2.0B
P/E Ratio—
EPS$-0.43
Dividend Yield—
Dividend / Share—
ROE-39.5%
Profit Margin-102.1%
Debt / Equity—
Trading
Volume6.2M
Avg Volume (10D)—
Shares Outstanding347.2M
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—